Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Distinct Clinical Course of EGFR Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib

Distinct Clinical Course of EGFR Results of Testing of 1118 Surgical Specimens and Effects of... ORIGINAL ARTICLE Distinct Clinical Course of EGFR-Mutant Resected  Lung Cancers Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib Sandra P. D’Angelo, MD,* Yelena Y. Janjigian, MD,* Nicholas Ahye, BA,* Gregory J. Riely, MD, PhD,* Jamie E. Chaft, MD,* Camelia S. Sima, MD, MS,† Ronglai Shen, PhD,† Junting Zheng, MS,† Joseph Dycoco, BA,‡ Mark G. Kris, MD,* Maureen F. Zakowski, MD,§ Marc Ladanyi, MD,§ Valerie Rusch, MD,‡ and Christopher G. Azzoli, MD* survival HR 0.43 (95% CI: 0.26–0.72, p = 0.001), and a trend toward Background: EGFR and KRAS mutations are mutually exclusive improved OS. and predict outcomes with epidermal growth factor receptor (EGFR) Conclusions: Patients with resected stage I–III lung cancers and tyrosine kinase inhibitor (TKI) treatment in patients with stage IV EGFR mutation have a lower risk of death compared with patients lung cancers. The clinical significance of these mutations in patients without EGFR mutation. This may be because of treatment with with resected stage I–III lung cancers is unclear. EGFR TKIs. Patients with, and without KRAS mutation have similar Methods: At our institution, resection specimens from patients OS. These data support reflex testing of resected lung adenocarcino - with stage I–III lung adenocarcinomas are tested for the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Distinct Clinical Course of EGFR Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib

Azzoli, Christopher G.
Journal of Thoracic Oncology , Volume 7 (12) – Dec 1, 2012
Download PDF
8 pages

Loading next page...
 
/lp/wolters-kluwer-health/distinct-clinical-course-of-egfr-results-of-testing-of-1118-surgical-088rAw9to9

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2012 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
eISSN
1556-1380
DOI
10.1097/JTO.0b013e31826bb7b2
pmid
23154553
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Distinct Clinical Course of EGFR-Mutant Resected  Lung Cancers Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib Sandra P. D’Angelo, MD,* Yelena Y. Janjigian, MD,* Nicholas Ahye, BA,* Gregory J. Riely, MD, PhD,* Jamie E. Chaft, MD,* Camelia S. Sima, MD, MS,† Ronglai Shen, PhD,† Junting Zheng, MS,† Joseph Dycoco, BA,‡ Mark G. Kris, MD,* Maureen F. Zakowski, MD,§ Marc Ladanyi, MD,§ Valerie Rusch, MD,‡ and Christopher G. Azzoli, MD* survival HR 0.43 (95% CI: 0.26–0.72, p = 0.001), and a trend toward Background: EGFR and KRAS mutations are mutually exclusive improved OS. and predict outcomes with epidermal growth factor receptor (EGFR) Conclusions: Patients with resected stage I–III lung cancers and tyrosine kinase inhibitor (TKI) treatment in patients with stage IV EGFR mutation have a lower risk of death compared with patients lung cancers. The clinical significance of these mutations in patients without EGFR mutation. This may be because of treatment with with resected stage I–III lung cancers is unclear. EGFR TKIs. Patients with, and without KRAS mutation have similar Methods: At our institution, resection specimens from patients OS. These data support reflex testing of resected lung adenocarcino - with stage I–III lung adenocarcinomas are tested for the

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Dec 1, 2012

References

  • The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours
    Goldstraw
  • Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group
    Pignon
  • Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials
    Song
  • Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer
    Arriagada
  • Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer
    Winton
  • Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group
    Ginsberg
  • Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial
    Douillard
  • Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    Maemondo
  • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
    Mitsudomi
  • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Mok
  • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
    Rosell
  • National Cancer Institute of Canada Clinical Trials Group Study BR.21. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
    Zhu
  • KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
    Pao
  • Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung
    Kim
  • Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma
    Kosaka
  • Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan
    Liu
  • LACE-Bio pooled analysis of the prognostic and predictive value of Kras mutation in completely resected non-small cell lung cancer
    Tsao
  • Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center
    D’Angelo
  • Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma
    Marks
  • Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations
    Janjigian
  • Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas
    Pan
  • The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer
    Chansky
  • A nonparametric test to compare survival distributions with covariate adjustment
    Heller
  • Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene
    Rizvi
  • A multicenter phase II trial of adjuvant erlotinib in patients with resected non-small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR): toxicity evaluation
    Neal
  • Time trends of surgical outcome in patients with non-small cell lung cancer
    Hanagiri
  • Prognosis of patients with resected non-small cell lung cancer: impact of clinical and pathologic variables
    Ravdin
  • Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise
    Azzoli
  • Biomarker analysis from completely resected NSCLC patients enrolled in an adjuvant erlotinib clinical trial (RADIANT)
    Richardson
  • A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinib in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19
    Goss
  • American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy
    Keedy
  • Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)
    Fukuoka
  • Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer
    Tsao
  • Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
    Oxnard
  • The SELECT study: a multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
    Neal